Rezolute (RZLT) Registration filing summary

Company overview and business model

• Late-stage rare-disease developer focused on therapies for refractory, debilitating hypoglycemia associated with hyperinsulinism (HI).

• Lead asset ersodetug is an IV monoclonal antibody that modulates insulin-receptor activity; half-life exceeds 2 weeks, with potential for monthly dosing and use across genetic or acquired HI.

• As of June 30, 2026, had 58 full-time U.S. employees: 40 in R&D and 18 in general and administrative functions.

Use of proceeds and capital allocation

• Net proceeds are intended for working capital, capital expenditures and general corporate purposes; any offering-specific allocation will be described in its supplement.

• May allocate proceeds to complementary businesses or technologies, although no acquisition plans, commitments or agreements existed as of Nov. 5, 2026; pending use, proceeds may be invested in investment-grade interest-bearing securities.

Risk factors and disclosures

• sunRIZE Phase 3 in congenital HI missed its primary finger-stick SMBG endpoint and key secondary CGM endpoint at the Week 24 evaluable window; FDA has not assessed ersodetug's approvability.

• upLIFT's first-half results included 7 of 8 participants meeting the primary responder criterion and discontinuing IV glucose; the eighth participant died after cancer progression and is counted as a non-responder.

• Product candidates require regulatory approvals and extensive testing; the filing directs investors to risk disclosures in the FY2026 10-K, quarter ended Sept. 30, 2026 10-Q and subsequent SEC filings.

• IP protection may be compromised, and trade secrets could become known or independently discovered; no assurance of adequate remedies is stated.